Minireviews

The Pharmacological Basis of Cannabis Therapy for Epilepsy

Doodipala Samba Reddy and Victoria M. Golub

Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M University Health Science Center, Bryan, Texas

Received October 21, 2015; accepted January 15, 2016

ABSTRACT

Recently, cannabis has been suggested as a potential alternative therapy for refractory epilepsy, which affects 30% of epilepsy, both adults and children, who do not respond to current medications. There is a large unmet medical need for new antiepileptics that would interfere with normal function in patients with refractory epilepsy and conditions associated with refractory seizures. The two chief cannabinoids are Δ9-tetrahydrocannabinol, the major psychoactive component of marijuana, and cannabidiol (CBD), the major nonpsychoactive component of marijuana. Claims of clinical efficacy in epilepsy of CBD-predominant cannabis or medical marijuana come mostly from limited studies, surveys, or case reports. However, the mechanisms underlying the antiepileptic efficacy of cannabis remain unclear. This article highlights the pharmacological basis of cannabis therapy, with an emphasis on the endocannabinoid mechanisms underlying the emerging neurotherapeutics of CBD in epilepsy. CBD is anticonvulsant, but it has a low affinity for the cannabinoid receptors CB1 and CB2; therefore the exact mechanism by which it affects seizures remains poorly understood. A rigorous clinical evaluation of pharmaceutical CBD products is needed to establish the safety and efficacy of their use in the treatment of epilepsy. Identification of mechanisms underlying the anticonvulsant efficacy of CBD is also critical for identifying other potential treatment options.

Introduction

Epilepsy is a chronic hyperexcitability disease that stems from various defects in neuronal networks in the brain that lead to recurrent seizures. Epileptic seizures are abnormal electrical discharges that can originate from a variety of brain regions and can cause alterations in behaviors, consciousness, and sensations. Epileptogenesis is the process by which a normally functioning brain becomes progressively epileptic owing to an injury or other risk factors such as stroke, infection, or prolonged seizures. Epilepsy may also develop because of an abnormality in neuronal wiring, an imbalance between excitatory and inhibitory neurotransmitters, or even a combination of these dynamics. In epilepsy patients, spontaneous seizures arise from an overexcited and hypersynchronous neural network and generally involves both cortical and subcortical structures. Owing to the large variation in types of epilepsy, it is classified as a spectrum disorder. Epileptic seizures can be classified into partial or generalized seizures. Partial seizures begin focally in a cortical site of the brain and account for approximately 60% of all epilepsies, whereas generalized seizures involve both hemispheres from the onset of epileptogenesis and account for the remaining 40% of epilepsy types (Duncan et al., 2006; Reddy, 2014). Epilepsy can be further divided into two groups: primary and secondary. Primary epilepsy (50%) is idiopathic (unknown cause). Secondary epilepsy (50%), also referred to as acquired epilepsy, may result from a number of conditions including neurotoxicity, traumatic brain injury, anoxia, metabolic imbalances, prolonged seizures attributable to drug withdrawal, tumors, or encephalitis (Reddy, 2014).

Epilepsy affects about 65 million people worldwide with an incidence of 20–70 new cases per 10,000 individuals per year (Barrese et al., 2010; Hesdorffer et al., 2013; Rektor et al., 2015). The disorder has devastating effects on one’s life, not only as a direct result of the clinical implications, but also because of the socioeconomic consequences, such as social isolation, educational difficulties, unemployment, and stigmatization. These social consequences often result in high comorbidity with psychiatric disorders, such as depression, and an increased suicide rate (Kros et al., 2015). The majority of new epilepsy diagnoses occur most frequently in children and the elderly. To date, no drug therapies exist for curing epilepsy; however, symptomatic relief can be found for up to 70% of patients.

ABBREVIATIONS: AEDs, antiepileptic drugs; AES, American Epilepsy Society; CB, cannabinoid; CB1, cannabinoid receptor type 1; AES, American Epilepsy Society; CB2, cannabinoid receptor type 2; CBD, cannabidiol; CBDV, cannabidivarin; CNS, central nervous system; NAC, nucleus accumbens; NMDA, N-methyl D-aspartate; THC, Δ9-tetrahydrocannabinol; TRPV, transient receptor potential vanilloid; 2-AG, 2-arachidonyl glycerol.
Antiepileptic drugs (AEDs) are the mainstay to achieving symptomatic seizure control; however, only two-thirds of epilepsy patients can be successfully treated by current AEDs (Iannotti et al., 2014). For the remaining 30% of epileptic patients, who suffer from intractable seizures that cannot be controlled by antiepileptic medications, treatment is often invasive, requiring surgical resection or neurostimulation.

There is a large unmet need for novel therapies that provide effective control of drug-resistant or refractory epilepsy and do not interfere with normal function (Perucca and Gilliam, 2012; Friedman and Devinsky, 2015). This task is more challenging in certain types of devastating pediatric epilepsy, such as Lennox-Gastaut, Doose, and Dravet syndromes. Recently, cannabinoids have been suggested as potential therapeutic alternatives for some patients with refractory seizures. Emerging experimental and pilot clinical studies suggest that cannabidiol, a nonpsychoactive constituent found within the cannabis plant, may act as an effective antiepileptic agent. Social media has created a lot of awareness and information sharing. There are many advocacy groups, including parents of children with refractory epilepsy who advocate CBD treatments and additional optional strategies. With the increase in preclinical data and publicized cases of cannabidiol-enriched strains of medical marijuana, advocacy groups have become more vocal about the possibility of cannabis use for the symptomatic treatment of epilepsy, especially within groups of parents with children who continue to experience refractory seizures. This article highlights the pharmacological basis of cannabis use for refractory epilepsy.

Marijuana, or cannabis, has been used since the 19th century for controlling epileptic seizures (Gowers, 1881). Marijuana is a colloquial term given to the dried flowers, stems, and leaves of a 1–5 m weed that originated in Asia. Cannabis belongs to the plant family Cannabaceae, of which there are three main species that can differ in biochemical components: Cannabis sativa, Cannabis indica, and the lesser known Cannabis ruderalis (Baron, 2015). The cannabis plant contains over 200 compounds referred to as cannabinoids (ElSohly and Gul, 2014). Among these are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), both the focus of recent studies. THC has potent psychoactive effects, including causing feelings of euphoria and altered sensory perception. Withdrawal symptoms, such as irritability and disturbances in sleep, result from abrupt discontinuation of long-term use of THC. Thus, THC is classified as a schedule I controlled substance (high abuse potential and little medical use). Efforts to develop therapeutic agents with THC as a basis yielded dronabinol (Marinol), which is used clinically for the control of nausea and moderate pain in cancer therapeutics. The unwanted psychoactive effects and withdrawal symptoms experienced by long-term use make THC a less probable therapeutic option for epilepsy. CBD, however, is another major component of cannabis and does not exert psychoactive effects. Products containing concentrated CBD have been advanced as helpful for refractory seizure control (Blair et al., 2015). The targeted actions of CBD in the brain are complex, involving both neuronal and non-neuronal targets, thus the pharmacological mechanisms of CBD treatment in epilepsy have yet to be fully elucidated. Molecular targets of THC and CBD, as well as some of the actions exerted by these compounds are listed in Table 1.

Experimental and Clinical Studies of Cannabis in Epilepsy

There is a growing awareness about medical marijuana and CBD-enriched products. Historically, in China marijuana has been used to treat rheumatism, pain, and convulsions (Maa and Figi, 2014). The use of marijuana was once not as politically charged as it is now. The prohibition movement of America, beginning at the turn of the 20th century, started the ban on several drugs, including cocaine, opium, and marijuana. Cannabis was available over-the-counter in the United States up until 1941, following passage of the Marijuana Tax Act of 1937, which restricted access to it. The Controlled Substance Act of 1970 classified cannabis as Schedule I, making its distribution and use illegal (Mechoulam, 1986). After the Controlled Substance Act of 1970 was passed, testing and research with medical marijuana and its constituents was heavily controlled, therefore making experimentation more difficult.

Currently, the FDA has not yet approved the use of medical marijuana for any indication; however, 23 states and Washington, DC, have made provisions for the use of cannabis as a therapeutic agent for some conditions. Additionally, four states (Alaska, Colorado, Oregon, and Washington) have also legalized recreational use of marijuana. This has led to burgeoning interest in the therapeutic potential of medical marijuana and its major constituents. Though the majority of cannabis research investigates the use of specific cannabinoids, a limited array of studies show clinically significant evidence of analgesic effects from smoking or ingesting whole-plant marijuana. The primary focus of these studies was symptomatic relief of neuropathic pain. Two FDA-approved prescription cannabinoids are currently available for the treatment of chemotherapy-induced nausea and vomiting: dronabinol (Marinol) (a synthetic Δ9-THC) and nabilone (Cesamet) (a Δ9-THC congener). Sativex, a clinical medication that combines both THC and CBD has been investigated for the alleviation of neuropathic pain for adults suffering from multiple sclerosis, and for symptomatic relief of cancer pains (Pertwee, 2012). Currently, two cannabis-based products with a high CBD content are being tested in clinical trials for such refractory epilepsies as Dravet and Lennox-Gastaut syndromes: Epidiolex and Realm Oil. Epidiolex is an oil-based product with >98% CBD and <3% THC. Realm Oil is an extract of a strain of medical marijuana with a CBD/THC ratio of 16:1. Neither product has been approved by the FDA or any other national regulatory agency.

Experimental Studies. Cannabinoids have antiepileptic effects in animals (Blair et al., 2015). CBD and its variants have been tested in several animal epileptic models, including maximal electroshock (Hill et al., 2012; Jones et al., 2015), pentylentetrazol (Jones et al., 2010, Hill et al., 2012, 2013), pilocarpine (Jones et al., 2012, Hill et al., 2013), penicillin (Jones et al., 2012), audiogenic seizures (Hill et al., 2012, 2013), 6-Hz (Jones et al., 2015), subcutaneous metrazol threshold test (Jones et al., 2015), and cobalt implantation (dos Santos et al., 2015). In most of these paradigms, CBD consistently showed anticonvulsant effects. Additionally, Jones et al. (2015) assessed CBD’s effect on minimal muscular and neurologic impairment using a rotor rod test, and they reported CBD treatment was well tolerated in both mice and rats. Another recent study observed both additive and antagonistic effects of CBD when combined with other AEDs. A
Comparative pharmacology of the cannabinoids THC and CBD

Several cannabinoids are known to bind to multiple targets in the CNS and exert effects at low micromolar and nanomolar concentrations. Both Δ⁹-THC and CBD have shown anticonvulsant effects in preclinical models of epilepsy, as well as production of other actions such as acting as an anti-inflammatory or neuroprotective agent. The nonselective actions of cannabinoids present a potential issue when used as a therapeutic option, as many questions about the safety and efficacy of these compounds remain unanswered.

### Table 1

<table>
<thead>
<tr>
<th>Cannabinoid Type</th>
<th>Chemical Structure</th>
<th>Pharmacological Actions</th>
<th>Potential Targets</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Δ⁹-Tetrahydrocannabinol (Δ⁹-THC)</td>
<td><img src="image" alt="Δ⁹-Tetrahydrocannabinol" /></td>
<td>Anticonvulsant</td>
<td>CB₁ partial agonist</td>
<td>Cascio and Pertwee (2014); Pertwee and Cascio (2014); Friedman and Devinsky (2014); Blair et al. (2015)</td>
</tr>
<tr>
<td>Cannabidiol (CBD)</td>
<td><img src="image" alt="Cannabidiol" /></td>
<td>Anticonvulsant</td>
<td>CB₂ ligand</td>
<td>Cascio and Pertwee, 2014; Pertwee and Cascio, 2014; Friedman and Devinsky, 2014; Blair et al. (2015)</td>
</tr>
</tbody>
</table>

A significant synergistic interaction was found between levetiracetam and CBD at a 1:1 fixed ratio; clobazam and carbamazepine both produced antagonistic interactions at a 1:3 fixed ratio (Smith et al., 2015).

A succession of experiments examined the effects of THC and CBD for controlling seizures in different animal models of epilepsy (Wallace et al., 2001, 2002, 2003). Both THC and CBD produced anticonvulsant effects in rodents (Wallace et al., 2001). Akin to phytocannabinoids, the endogenous cannabinoid anandamide produced an anticonvulsant effect (Wallace et al., 2002). Moreover, certain cannabinoid-receptor antagonists cause status epilepticus-like proeiseizure activity (Deshpande et al., 2007). Experimental studies linked the cannabinoid receptors type 1 (CB₁) to the anticonvulsant activity of THC but did not mention the mechanistic aspects of CBD. A variety of mechanisms are linked to CBD protective effects, and they are described in the next sections (Consroe et al., 1982; Jones et al., 2010; Patel et al., 2014). Overall, strong evidence indicates the anticonvulsant activity of CBD compounds (Wallace et al., 2001; Blair et al., 2015), but the exact neuronal mechanisms are unclear. This is further elaborated in the next subsection.

In addition to the preclinical CBD trials, investigations of the synergistic interactions and additive effects of CB₁ receptor agonists and standard antiepileptic drugs have been conducted. WIN55212, a CB₁ receptor agonist with effects similar to THC, was given at low doses in tandem with low doses of ethosuximide (Luszczki et al., 2011a), phenobarbital (Luszczki et al., 2011a, 2011b), valproate (Luszczki et al., 2011a, 2011b), carbamazepine (Luszczki et al., 2011b), phenytoin (Luszczki et al., 2011b), and diazepam (Naderi et al., 2008) to produce enhanced anticonvulsant effects in mice. In a similar fashion, the synthetic CB₁ receptor agonist arachidonyl-2′-chloroethylamide was tested with low dose injections of naltrexone (Bahreman et al., 2008) and phenobarbital (Luszczki et al., 2010) to produce an additive anticonvulsant effect in mice. It is important note, however, that evidence suggests that WIN55212 not only enhances the antiseizure effects of common antiepileptic medications such as carbamazepine, phenytoin, phenobarbital, valproate, and ethosuximide in mice but also the negative side-effects of these drugs, i.e., impairment of motor co-ordination, as well as impairment of long-term memory (Luszczki et al., 2011a, b; Pertwee, 2012). This is in contrast with the actions of the CB₁-selective agonist arachidonyl-2′-chloroethylamide, which enhances the anticonvulsant effects of phenobarbital without changing the impairment of motor co-ordination, long-term memory, or skeletal muscle strength generally seen with this barbiturate (Luszczki et al., 2010). The cerebellum and neocortex are two regions of the brain that are involved in the initiation and coordination of movement. Humans express a higher proportion of CB₁ in the limbic system and cerebral cortex and have lower expression in the cerebellum than do rats, which may illuminate the suggestion that motor function is more compromised in rodents when they are administered cannabinoids (Pertwee, 2008).

**Clinical Studies.** In contrast to a great deal of preclinical data, supportive clinical data are rather limited. Much of the information concerning the clinical effects of marijuana in human patients has been either anecdotal or survey material. At present, 19 small trials are underway to study whether nonpsychoactive cannabinoids may be useful as antiepileptics (ClinicalTrials.gov). Table 2 provides a summary of various clinical studies of cannabis or CBD products in epilepsy.
TABLE 2
Chronological summary of clinical reports and surveys on the use of cannabinoids for epilepsy (1949–2015)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study</th>
<th>Subjects</th>
<th>Study Details</th>
<th>Results</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davis and Ramsey (1949)</td>
<td>Case series of 5 institutionalized children with mental retardation and epilepsy</td>
<td>5</td>
<td>Treated for 10 weeks with two isomeric-3 homologs of THC</td>
<td>3 patients responded at least as well to their previous AEDs, the remaining 2 had significant decrease in seizures</td>
<td>None reported</td>
</tr>
<tr>
<td>Consroe et al. (1975)</td>
<td>Case study of a 24-year old male with refractory epilepsy</td>
<td>1</td>
<td>Patient would self-treat with 2–5 joints per night while continuing to take prescribed medications</td>
<td>Nearly seizure free with daily marijuana use in tandem with prescribed AEDs for the duration of the study; 0/5 placebo group had seizure improvement</td>
<td>None reported; patient was not able to completely control seizures on marijuana alone</td>
</tr>
<tr>
<td>Mechoulam and Carlini (1978)</td>
<td>Placebo-controlled trial in epileptic patients</td>
<td>9 total; 4 treatment, 5 placebo</td>
<td>Treated with 200 mg of CBD in tandem with prescriptions for 3 months</td>
<td>2/4 treatment group were seizure-free for the duration of the study; 0/5 placebo group had seizure improvement</td>
<td>None reported</td>
</tr>
<tr>
<td>Cunha et al. (1980)</td>
<td>Placebo-controlled trial in teenagers and adults with TLE</td>
<td>15 total; 8 treatment, 7 placebo</td>
<td>Treated with 200–300 mg CBD or placebo per day for up to 4.5 months</td>
<td>4/8 were seizure-free for the duration of the study; 3 others showed partial improvement</td>
<td>Somnolence in some participants</td>
</tr>
<tr>
<td>Ames and Cridland (1986)</td>
<td>Placebo-controlled trial in patients with uncontrolled seizures</td>
<td>12 total; 6 treatment, 6 placebo</td>
<td>Treated with 200–300 mg CBD or placebo per day for 1 month</td>
<td>Little difference was reported between the treatment and placebo groups, although not much detail was given</td>
<td>Somnolence was reported as a side effect for some participants</td>
</tr>
<tr>
<td>Gedde and Maa (2013)</td>
<td>Survey of parents of pediatric epilepsy patients who had been taking Realm Oil as a therapeutic option. Diagnoses included Doose, Dravet, and Lennox-Gastaut, as well as other refractory epilepsies</td>
<td>11</td>
<td>Realm oil (extract of 16:1 CBD cannabis plant) was given as a therapeutic option for at least 3 months. Average dose was between 4–12 mg/kg per day.</td>
<td>11/11 patients experienced a reduction in weekly motor type seizure frequency; 8/11 experienced almost 100% reduction; 1/11 had a 75% reduction; 2 reported 20–45% reduction</td>
<td>Sedation and unsteadiness</td>
</tr>
<tr>
<td>Porter and Jacobson (2013)</td>
<td>Survey was conducted of parents who had children with epilepsy who were currently using CBD-enriched cannabis products</td>
<td>19</td>
<td>Parents of pediatric epilepsy patients were surveyed on their children’s seizure frequency and duration</td>
<td>16/19 responders reported a reduction in seizure frequency while children were taking medical marijuana; others reported beneficial effects like improved sleep and mood</td>
<td>Drowsiness and fatigue were reported by some parents</td>
</tr>
<tr>
<td>Devinsky et al. (2014b)</td>
<td>Prospective observational study including both children and adults with treatment-resistant epilepsies where CBD treatment was added to their daily AED regimen</td>
<td>23</td>
<td>Epidiolex (98% CBD oil) was given to patients for 3 months in tandem with previous prescriptions at a maximum dose of 25 mg/kg per day</td>
<td>9/23 patients experienced &gt;50% reduction in seizures; median reduction in seizures 32% for all patients; 1/23 had increased seizure activity</td>
<td>Somnolence and fatigue</td>
</tr>
<tr>
<td>Friedman et al. (2014)</td>
<td>Drug-drug interaction trial between Epidiolex (CBD) and clobazam in epileptic patients</td>
<td>33 total; 17 CBD treatment, 16 clobazam control</td>
<td>Treated with CBD 25 mg/kg per day in tandem with clobazam</td>
<td>A median change in AED serum levels was found for clobazam of 8.3%. 7/17 patients taking clobazam required a clobazam dose reduction owing to a drug-drug interaction</td>
<td>None reported</td>
</tr>
<tr>
<td>GW Pharmaceuticals plc (2015)</td>
<td>Press release providing safety and efficacy data for Epidiolex treatment trials</td>
<td>58</td>
<td>Epidiolex (98% CBD oil) was given to patients for at least 12 weeks in tandem with their previous prescriptions</td>
<td>Median reduction in seizure frequency was 43% for all patients</td>
<td>Fatigue, somnolence, diarrhea, and changes in appetite were observed in some patients</td>
</tr>
</tbody>
</table>

(continued)
A Cochrane systematic review of CBD-enriched therapies for the treatment of epilepsy (Gloss and Vickery, 2014) searched for randomized, controlled clinical trials that showed direct evidence of the anticonvulsant effects of medical marijuana or CBD in human seizures. They identified only four studies that fit their efficacy criteria, with a total sample of 48 participants in clinical studies, randomized to placebo or to studies that fit their efficacy criteria. In one case, a 24-year-old man self-treated with 2–5 joints per night in addition to his prescribed antiepileptic medications and experienced a reduction in seizures (Consorto et al., 1975). The second case, which convinced many parents with epileptic children to move to Colorado, featured a young girl named Charlotte, who had been diagnosed with severe Dravet Syndrome. After she was started on a low dose of a sublingual preparation of a cannabis extract in tandem with her previously prescribed medication, Charlotte experienced a 90% decrease in total seizures after 3 months of treatment; patient was able to wean off of previously prescribed medication. None reported

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study</th>
<th>Subjects</th>
<th>Study Details</th>
<th>Results</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maa and Figi (2014)</td>
<td>Case study of a 5-year-old female with severe Dravet syndrome</td>
<td>1</td>
<td>Patient was given low dosage of sublingual preparation of low THC, high CBD</td>
<td>&gt;90% decrease in total seizures after 3 months of treatment; patient was able to wean</td>
<td>None reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>marijuana extract daily</td>
<td>off of previously prescribed medication</td>
<td></td>
</tr>
<tr>
<td>Geoffrey et al. (2015)</td>
<td>Drug-drug interaction trial between CBD and clobazam in patients with refractory epilepsy</td>
<td>25 total; 13 CBD treatment, 12 clobazam control</td>
<td>Treated with CBD 25 mg/kg per day in tandem with prescribed clobazam for 4 weeks</td>
<td>11/13 patients experienced a 50–55% decrease in seizure activity; 2/13 patients had an increase in seizure activity</td>
<td>Drowsiness, ataxia, and irritability were observed in some patients</td>
</tr>
<tr>
<td>Hansen et al. (2015)</td>
<td>Survey conducted at University of Alabama at Birmingham and Children’s of AL medical centers on the relationship between socioeconomic status and recipients of CBD oil epilepsy trials</td>
<td>23</td>
<td>Questions asked on household income, level of education, and medical insurance</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Oldham et al. (2015)</td>
<td>Observational study of children and adolescents who received Epidiolex as an addition to their daily AED regimen</td>
<td>25</td>
<td>Participants were treated with up to 25 mg/kg per day of Epidiolex (98% CBD oil) for up to 12 months. Baselines were checked at 3 months and 12 months.</td>
<td>32% of patients had a more than 50% seizure reduction 12 Months: 40% of patients (10) had above 50% seizure reduction</td>
<td>Food aversion, diarrhea, changes in diet, or weight loss</td>
</tr>
<tr>
<td>Press et al. (2015)</td>
<td>Retrospective survey on pediatric patients with varying types of epilepsy who were taking oral cannabis extracts</td>
<td>75</td>
<td>Survey conducted on seizure frequency and duration</td>
<td>57% of responders reported improvement of seizure duration and frequency</td>
<td>None reported</td>
</tr>
</tbody>
</table>
responders also noted other beneficial effects such as improved sleep and mood (Porter and Jacobson, 2013). Another survey reported 8/11 responders had experienced an almost 100% reduction in seizure activity when taking Realm Oil, an extract of Charlotte’s Web, as a therapeutic option (Gedde and Maa, 2013). Furthermore, 75 patients or caregivers who had started taking oral cannabis extracts for refractory epilepsy were asked about their perception of the efficacy of the products. Of the responders, 57% reported improvement to either seizure duration or frequency. The responder rate varied on the basis of the type of epilepsy: Dravet 23%, Doose 0%, and Lennox-Gastaut syndrome 89%. However, there was a discrepancy in responder rate between patients with pre-existing residency in Colorado and those patients who had moved to Colorado seeking oral cannabis treatments, finding that those patients who had moved to Colorado were more than three times more probable to report a >50% seizure reduction than those who had a pre-existing residency (Press et al., 2015). In a press release, GW Pharmaceuticals (2015) reported results on both efficacy and safety data for patients who had received Epidiolex (>97% CBD, <3% THC) as part of their daily regimen for at least 12 weeks. Data from 58 patients was reported from those suffering from a range of treatment-resistant epilepsies including Dravet syndrome. The median reduction in seizure frequency was 43% for all patients. The most frequently stated side effects included fatigue and somnolence; however, diarrhea and changes in appetite were also observed, with ~80% of patients reporting at least one side effect.

Few prospective trials have been conducted that involve the use of isolated cannabinoids as a therapeutic option for epilepsy. As mentioned previously, the Gloss and Vickery Cochrane study found only four placebo-controlled studies using CBD as a treatment of epilepsy. In all four studies, patients with uncontrolled seizures were randomized into either placebo or CBD groups. The patients in the experimental groups were given between 200–300 mg of CBD. Of the four studies, two reported a difference in seizure frequency between the two groups (Mechoulam and Carlini, 1978; Cunha et al., 1980), whereas the remaining two studies provided few details but suggested little or no difference in seizure frequency between placebo and CBD groups (Ames and Cridland, 1986; Trembly and Sherman, 1990). Recently, there has been a surge in clinical trials investigating the additive effects of CBD in daily AED regimens in both children and adults. In 2014, a prospective observational study reported 923 patients experienced a greater than 50% decrease in seizures, with a median reduction in seizures of 32% for all patients when treated with 25 mg/kg per day of Epidiolex in tandem with prescribed AEDs (Devinsky et al., 2014b). Similar reports were made in a 2015 study with 25 patients (Oldham et al., 2015). In addition to these trials, two additional studies were performed investigating drug-drug interactions between CBD products and frequently prescribed AEDs. Both studies found a change in serum levels when CBD products and clobazam were taken in tandem (Friedman et al., 2014; Geffrey et al., 2015). For those patients, the dose of clobazam was reduced. A 50–55% decrease in seizures was experienced in 11/13 patients; however, the remaining 2/13 had an increase in seizure activity (Geffrey et al., 2015). In all the human trials, no major adverse effects were mentioned; however, minor side effects included somnolence, fatigue, diarrhea, and changes in appetite.

Recently, a survey in Alabama highlighted the relationship between socioeconomic status and admission into CBD oil epilepsy trials. It found that the trial participants were racially/ethnically monolithic (white) and typically in higher income groups with private medical insurance (Hansen et al., 2015). This contrasts with the region’s relatively higher proportion of African Americans of lower income, and clearly documents a disadvantage for this group with respect to epilepsy care. The American Epilepsy Society (AES) has released a statement on the use of medical marijuana in the treatment of epilepsy but drew no conclusion at present owing to a lack of data; however, the AES supports well-controlled studies that will lead to a better understanding of epilepsy and the effects cannabinoids in relation to development of safe and effective treatment options for those affected by the disease. All of the studies mentioned herein involved epileptic patients, both children and adults with varying forms of refractory epilepsy, and reported moderate seizure reduction with only mild side effects. Furthermore, as a result of the lack of conclusive data, fewer epilepsy specialists support prescribing CBD products and medical marijuana to their patients compared with other medical professionals, or recipients of these therapeutics, according to a survey conducted by Epilepsia (Mathern et al., 2015).

In essence, these studies also reveal tolerability, safety, and drug interactions with cannabis use. CBD is well tolerated in humans with doses up to 600 mg without severe reactions or psychotic symptoms (Table 2). No significant central nervous system (CNS) effects were noted in the few small placebo-controlled studies. However, when CBD is taken orally, it first undergoes an extensive first-pass metabolism with low bioavailability (~6%). The half-life of CBD, when administered this way in humans, is approximately 1–2 days. CBD is a powerful inhibitor of many cytochrome P450 isozymes, including CYP2C and CYP3A, indicating a potential for drug-drug interactions when taken with other medications.

One of the most serious concerns of cannabinoid therapeutics is their potential for abuse. It has been proposed that cannabinoids modify reward mechanisms (Gardner and Vorel, 1998) and, as with other drugs abused for recreational uses, they can increase dopamine release to the nucleus accumbens (NAC) (Tanda et al., 1997). However, synthetic cannabinoids (WIN55212-2 and CP55940) were not able to increase dopamine levels within acute NAC slice preparations, nor were CB1 receptors particularly dense in the ventral tegmental area where the mesolimbic dopaminergic pathway originates (Malleux and Vanderhaegen, 1992; Tsou et al., 1998; Szabo et al., 1999). This data indicates that the forebrain regions that project to the NAC may be indirectly involved with the elevation of dopamine. Furthermore, glutamatergic neurons in the amygdalae basolateralis anterior increase their activity when rewarding stimuli are presented (Muramoto et al., 1993). It has been suggested that cannabinoids modulate the dopaminergic pathways by reducing the tonic GABAergic inhibitory control over pyramidal cells in the basolateral complex of the amygdala (Katona et al., 2001).

Preclinical and clinical investigations on the safety and efficacy of cannabinoid products continue to be pursued for more conclusive answer to these concerns.
Pharmacological Basis of Cannabis Use in Epilepsy

Despite such widespread therapeutic interest in cannabis, the mechanistic rationale for cannabis use in epilepsy remains an enigma. The pharmacological mechanisms underlying such therapeutic claims for epileptic seizures are poorly understood. At the systems level, it is probable that CBD or related constituents in the cannabis can affect the endocannabinoid system and thereby modulate neural networks involved in generation or spread of hyperexcitability and epileptic seizures. In this context, the specificity and nonspecificity of CNS actions of cannabis are important aspects for epilepsy therapeutics. This distinction between specific and nonspecific drug mechanisms is often difficult to define in the case of cannabis use or even with CBD-predominant products, mostly because of limited data on the dose-response relationship of the drug for the intended therapeutic efficacy. The therapeutic dynamics become even more complex if the drug has a broad spectrum of targets, which can result in unpredictable activity if the drug product contains multiple active compounds or is not produced according to standard manufacturing practices. Although control of epileptic seizures is the goal when administering a cannabis product, potential off-target effects can possibly cause other unintended side effects.

**Endocannabinoid System.** The primary pharmacological effects of cannabinoids are attributable to its interaction with cannabinoid (CB) receptors in the CNS and also in the periphery. The presence of cannabinoid receptor types 1 and 2 (CB1/CB2) in the brain initiated the investigation and discovery of endogenous cannabinoids such as anandamide and 2-arachidonyl glycerol, which are ligands for CB1 receptors (Koppel et al., 2014). The name “anandamide” is derived from the Sanskrit word “anand” for bliss or happiness with the suffix “-amide”. Anandamide is related to CBD and shares some of the same molecular targets. Cannabinoid receptors are ubiquitous throughout the CNS and are often coexpressed to presynaptic G, protein-coupled receptors (Hofmann and Frazier, 2013). Both CB1 and CB2 receptors are linked to G, and inhibition of adenyl cyclase activity. Activation of CB1 receptors results in inhibition of glutamate release. The two primary natural endogenous ligands for these receptors are the arachidonic acid derivatives anandamide (N-arachidonoyl-ethanolamine) and 2-arachidonyl glycerol (2-AG) (Devane et al., 1992; Maa and Figi, 2014). The strong lipophilic nature of cannabinoids provides for efficient targeting of intracellular sites, stimulating increases in intracellular calcium concentrations in a wide range of neuronal cell types. Endocannabinoid activity has also been observed in a significant number of immune cells types, including (but not limited to): basophils, dendritic cells, lymphocytes, macrophages, and monocytes (Matias et al., 2002). Anandamide and 2-AG are rapidly hydrolyzed by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (Dinh et al., 2002a, b; Nomura et al., 2011). Anandamide and 2-AG have been identified around both GABAAergic and glutamatergic neurons involved in regulating excitability and seizure susceptibility, which may explain some of the anticonvulsant properties of these molecules (Maa and Figi, 2014).

The two types of endocannabinoid receptors share 44% amino acid homology, have seven transmembrane domains, and are associated with G, protein-coupled receptors, linking them to signaling cascades within the cell (Munro et al., 1993). Both the CB1 and CB2 receptors are activated by the endocannabinoids anandamide and 2-AG. The CB1 receptor is expressed presynaptically on both glutamatergic and GABAAergic interneurons throughout the CNS, as well as throughout the periphery (Gerard et al., 1991). It is principally accountable for the psychoactive effects associated with THC, and stimulation of this receptor also plays a role in regulating stress responses, pain, lipogenesis, and energy regulation. In contrast, the CB2 receptors are predominantly expressed throughout the immune system, though sparsely expressed within the CNS as well, generally located on microglial cells (Cabral et al., 2015). The complexity of the endocannabinoid system throughout the CNS and the periphery may offer various targets to modulate the endocannabinoid signaling (Hill et al., 2010; Häring et al., 2011; Iannotti et al., 2014; Naderi et al., 2015). There is also evidence of dysfunction in the endocannabinoid systems in epilepsy. Patients who were newly diagnosed with temporal lobe epilepsy have significantly lower levels of anandamide in cerebrospinal fluid compared with healthy counterparts (Ludányi et al., 2008; Romigi et al., 2010).

**Δ^9-Tetrahydrocannabinol.** THC is the most abundant compound found in cannabis. THC is believed to be responsible for the psychoactive effects commonly associated with smoking marijuana, and is therefore associated with many of the diverse effects of marijuana, including changes in human cognition and perception (Hofmann and Frazier, 2013). THC acts as a partial agonist of CB1 receptors, which are found primarily in the CNS, as well as on CB2 receptors located primarily on the cells of the immune system. There is some discrepancy in the investigation of the anticonvulsant effects of THC. Much of the research suggests that THC produces anticonvulsant effects and could therefore be a potential constituent in epilepsy therapeutics (Consoer et al., 1982; Wallace et al., 2001). The mechanism by which THC produces these anticonvulsant effects is suggested to be through the CB1 receptors (Detryniecki and Hirsch, 2015). There are also a few conflicting studies that show no decrease in seizure activity in some cases and more frequent seizures in others (Karler et al., 1984; Devinsky et al., 2014a; dos Santos et al., 2015). The potential for tolerance and the psychoactive effects of THC could be the critical limiting factors for advancing the clinical potential of THC.

**Cannabidiol.** CBD, a major phytocannabinoid found in cannabis, accounts for up to 40% of the plant’s extract (Campos et al., 2012). Owing to its lack of psychoactive properties and the low rate at which a tolerance develops, CBD is considered to have a much wider therapeutic potential for epilepsy compared with THC. CBD has anticonvulsant (Consoer et al., 1982, Martin et al., 1987; Devinsky et al., 2014a), anti-inflammatory (Malfait et al., 2000; Li et al., 2013), and antitumorigenic activities (McAllister et al., 2011). Although CBD has a low affinity for both the CB1 and CB2 receptors, at high levels it can act as an indirect CB1 antagonist and has been shown to affect the threshold of seizures in some animal studies (Wallace et al., 2003). In addition, CBD is known to downregulate fatty acid amide hydrolase and 5-lipoxygenase enzymes (Capasso et al., 2008), inhibit the uptake of adenosine (Liu et al., 2008), and bind to both transient receptor potential vanilloid 1.
Basal ganglia, cerebellum and neocortex, spinal cord, hippocampus (Elphick and Egertová, 2001). A limited number of investigations have reported changes in 5-HT receptor function or expression in epileptic patients; however, it remains uncertain whether this is a cause of the disease or a factor in epileptogenesis (Theodore et al., 2007; Ibeas Bih et al., 2015). In addition, CBD may also exert antioxidant effects (Hampson et al., 1998). Therefore, when CBD products are administered, it can be difficult to unambiguously distinguish between effects of, for example, cannabinoid receptor- and noncannabinoid-mediated actions, which is an important consideration when investigating new therapeutic options.

Cannabinidivarin (CBDV) is a propyl analog of CBD (Vollner et al., 1969). CBDV also elicits anticonvulsant effects in animal models (Hill et al., 2012). There is limited knowledge about the mechanisms of CBDV, although it has been reported that CBDV acts via the CB2 receptors and other targets (Scutt and Williamson, 2007; Iannotti et al., 2014).

Cannabinoid CB1 Receptors. CB1 receptors are widely expressed throughout the CNS, specifically located within the basal ganglia, cerebellum and neocortex, spinal cord, hippocampus, and amygdala. The CB1 receptors are found on axonal terminals near the release sites of the presynaptic neuron and reduce neurotransmitter release (Alger, 2014). The influence on both excitatory and inhibitory synapses leads to potentially complex outcomes. The CB1 receptors expressed within in the basal ganglia are responsible for the well documented effects on locomotor activity in rodents (Lee et al., 2006; Bosier et al., 2010; Veeraraghavan and Nistri, 2015). As in other areas of the brain, these receptors inhibit the release of both glutamate and GABA, depending on the type of neuron expressing the receptor. Thus, CB1 activation inhibits both excitation and inhibition in a dose-dependent triphasic pattern. Locomotor activity is decreased with both high and low doses, whereas moderate doses were shown to heighten motor activity in rodents (Elphick and Egertová, 2001).

CB1 receptors in the spine, particularly those on interneurons in the dorsal horn, are responsible for much of the documented analgesic effects of cannabis. Layers 1 and 2 of the dorsal horn, which target a variety of peripheral nociceptive terminals, contain the heaviest expression of CB1 receptors (Hoheisel et al., 2011). It is thought that endogenous cannabinoids exert an analgesic effect through these receptors (Elphick and Egertová, 2001).

CB1 receptors are densely located on the glutamate-releasing pyramidal cells of the cornu ammonis within the hippocampus, one of the major regions of the brain affected by epilepsy. By inhibiting the release of glutamate, these receptors indirectly block NMDA-modulated excitatory currents, and therefore suppress the initiation of the learning-memory–related phenomenon of long-term potentiation and long-term depression (Baron, 2015; Goodman and Packard, 2015). The expression of CB1 receptors in the rat hippocampus underwent a strong, plastic response following status epilepticus (Falenski et al., 2009). The basolateral complex exhibited heavy expression of CB1 receptors, whereas in other areas such as the central nucleus there was little expression of CB1 receptors (Katona et al., 2001).

Two important studies have increased the understanding of the endocannabinoid system, showing that it is promptly activated following seizure activity. The first showed that blocking the CB1 receptor in epileptic rats led to an increase in both seizure frequency and duration (Wallace et al., 2003). This study signified that CB1 activation is a response to seizure activity, rather than a cause, since this response was not elicited in control rats. In support of this insight, the researchers found the level of 2-AG increased in the hippocampus within 15 minutes after a single pilocarpine-induced seizure. Another study demonstrated glutamatergic neurons in the forebrain are predominately responsible for the cannabinoid-mediated protection against seizures (Marsicano et al., 2003).

Cannabinoid CB2 Receptors. CB2 receptors are found predominantly in the peripheral tissues of the immune system where they are primarily responsible for mediating the release of cytokines (Galiegue et al., 1995, Pertwee, 2006). CB2 receptors are localized on immune cells such as monocytes, B-cells, T-cells, and macrophages (Galiegue et al., 1995; Ashton and Glass, 2007; Basu et al., 2011). CB2 receptors are also expressed in the brain, though not as densely as CB1 receptors. Interestingly, the CB2 receptor is found primarily on microglia and not on neurons, unlike the CB1 receptor (Pertwee, 2006). Consequently, specific CB2 agonists are suggested as possible therapeutic targets for treatment of inflammation and pain, especially neuropathic pain. A study revealed that synthetic cannabinoid agonists of CB2 receptors exhibit changes in cAMP levels, causing inhibition of T cell signaling (Cheng and Hitchcock, 2007). The CB2 agonist JWH-015 was found to activate macrophages to remove β-amyloid protein from frozen human tissues (Tolón et al., 2009). This evidence suggests that CB2 receptors may also hold therapeutic potential for neurodegenerative diseases such as Alzheimer disease.

Conclusions and Perspectives

Cannabinoids are used to treat a variety of nervous system conditions (Wissel et al., 2006; Notcutt, 2015). Many ongoing trials on a diverse range of cannabinoids have shown them to be beneficial for epilepsy (Cunha et al., 1980; Wallace et al., 2001); however, other studies have shown that cannabis can have variable effects on seizures in different species (Meldrum et al., 1974; Martin and Consroe, 1976; Chiu et al., 1979). Preliminary evidence reveals therapeutic potential for cannabinoids, particularly CBD, to reduce seizure frequency and duration. In patient or caregiver surveys, the majority of responders claimed to observe beneficial effects or no significant effects of cannabis in epileptic children. The bulk of data suggests that cannabinoids exert at least partial protection in patients with rare forms of epilepsy, such as Dravet and Lennox-Gastaut syndromes. In many clinical trials cannabis was administered in tandem with the patient’s previously prescribed medications. Some of the patients were able to lower the dosage of the medications, and in some cases completely stop them, with no increase in seizures during the trial period.

Although cannabis has been used medicinally for centuries, it is only within the last few decades that our understanding of the mechanisms of the cannabinoid system and the potential benefit of these mechanisms has begun to accumulate.
Cannabinoids have anticonvulsant effects in animals. It is well known that they can exert a variety of effects in the CNS and the periphery. Their main target is the endocannabinoid system, which is involved in regulating neurotransmitter networks and other peripheral functions. This occurs through CB1 receptors, which are principally distributed throughout the brain, and through the CB2 receptors that are preferential for peripheral and immune tissues. Amid dozens of cannabinoids found in cannabis, so far two show medicinal promise. The first, THC (controlled substance), is the CB1 agonist that has potent anticonvulsant and psychoactive properties. The second, CBD (non-psychoactive substance), acting on CB2, lacks psychoactivity but modulates seizures and immune function. THC is a potent antiepileptic in both animals and humans; however, the relatively high rate of tolerance development and psychoactive properties diminish its therapeutic potential. CBD has also been shown to elicit anticonvulsant and anti-inflammatory effects in several studies. Although CBD has a low affinity for the CB1 and CB2 receptors, the exact mechanism by which this agent affects seizures remains unclear and perhaps involves more complex systems (Brodie et al., 2015). There are potential side effects of cannabis use that include psychiatric, sleep, and cognitive impairments. Marijuana use is not always thought of as an appropriate therapeutic option. Apart from THC, other cannabinoids found within marijuana have psychoactive properties and would thus be undesirable for therapeutics. New studies on cannabis use yield some insight on safety issues. Two recent studies explored the effect of cannabis on subcortical brain structures and brain maturation in adolescence in relation to risk of schizophrenia. Pagliaccio and colleagues (2015) analyzed the effects of cannabis use in a large sample (n = 483) of twins and siblings enrolled in the Human Connectome Project, 262 of whom reported using cannabis in their lifetime. Smaller left amygdala and right ventral striatum volumes were found in those participants who reported cannabis use, though differences were within the range of normal variation. French and colleagues (2015) found that cannabis use might affect the maturation of the cerebral cortex in adolescents with a risk of schizophrenia as shown by their polygenic risk score. These types of studies provide indications on the general safety of exposing young people to cannabis (Goldman, 2015).

December 2015, 19 clinical trials are progress are evaluating CBD for use in epilepsy treatment (see clinicaltrials.gov). Given the growing interest and clinical data, professional medical establishments have begun formulating guidelines about cannabis use for epilepsy. In 2014, the AES, the leading organization of clinical and research professionals in epilepsy, released a position statement on medical marijuana (www.aesnet.org/about_aes/position_statements). The essence of this statement includes: 1) Positive effects of the CBD are from anecdotal reports only with robust scientific evidence lacking to establish medical marijuana as a safe and effective treatment of epilepsy; 2) potential negative effects on learning, memory, and behavior; 3) should be studied using well founded research methods; 4) status as a Schedule 1 substance should be reviewed; and 5) the risk/benefit ratio does not currently support the use of marijuana for treatment of seizures at this time. Despite all of the controversial challenges of medical marijuana as a potential therapy for epilepsy, what is not disputed is the need for scientific investigation into cannabinoids to prove or disprove their safety and efficacy for epilepsy therapy. Since the mechanism of CBD’s seizure protection is unknown, identification of mechanisms driving anticonvulsant efficacy are additionally critical for helping to identify other potential treatment options.

Authorship Contributions
Wrote or contributed to the writing of the manuscript: Reddy, Golub.

References
Reddy and Golub

Din ThP, Freund TF, and Piennelli D (2002b) A role for monoglyceride lipase in 2-

367:1087–1100.


Neuroscience 18:1315–1320.

Neuropsychopharmacology, 1:657–658.

Koppel BS, Brust JCM, Fife T, Bronstein J, Youssef S, Gorenstein G, and Gloss D
(2014) Systematic review: efficacy and safety of medical marijuana in selected
neurological disorders: report of the Guideline Development Subcommittee of the

Kros L, Eiklmann Rooda OH, De Zeeuw CI, Hoebbeke FE, and Hoebbeke FE (2015)
Controlling cerebellar output to treat refractory epilepsy. Trends Neurosci 38:
787–797.

Lee J-D, Marzo V, and Brothie JM (2006) A role for vanilloid receptor 1 (TRPV1)
and endocannabinoid signalling in the regulation of spontaneous and L-DOPA
induced locomotion in normal and reserpine-treated rats. Neuropharmacology 51:
557–565.


thalmol Vis Sci 49:5526–5532.

 cannabinoid receptor and related molecular elements of the cannabinoid signalling

 cannabinoid CB1 receptor agonist and related molecular elements of the canna-

Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of
cannabinoid CB1 receptor agonist, on the protective action of the various anti-
epileptic drugs in the mouse maximal electroshock-induced seizure model. Prog

 cannabinoid CB1 receptor agonist, on the protective action of the various anti-
epileptic drugs in the mouse maximal electroshock-induced seizure model. Prog

Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of
cannabinoid CB1 receptor agonist, on the protective action of the various anti-
epileptic drugs in the mouse maximal electroshock-induced seizure model. Prog

Maj A, and Czuczwar SJ (2011a) Effects of WIN 55,212-2 mesylate (a synthetic
 cannabinoid CB1 receptor agonist and related molecular elements of the canna-

Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R,
and Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is
an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl
Acad Sci USA 97:5951–5955.

SC, Caggiato MG, Gutierrez SO, and van der Stelt M, et al. (2003) CB1 canna-
binoid receptors and on-demand defense against excitotoxicity. Science 302:
84–88.

Martin AR, Consroe P, Kane VV, Shah V, Singh V, Lander N, Mechoulam R,
and Srebnik M (1987) Structure-anticonvulsant activity relationships of cannabi-
dsins and related compounds: potential antiepileptic action of some cannabinoid

McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C,
44:5561–5566.